Esperion sues Daiichi Sankyo, $300 million milestone for aerobic drugs is not easy
No further details were given about the impact of Covid-19 on respondents. Japan, like many East Asian countries, has maintained strict pandemic restrictions until 2022, though others put in order.
Esperion sues Daiichi Sankyo, $300 million milestone for aerobic drugs is not easy Read More »